Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Renflexis
- Retacrit
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

video_2_edelbaum-mp4

October 8, 2018October 8, 2018

Published by

View all posts by

Published October 8, 2018October 8, 2018

Post navigation

Previous Post video_2_edelbaum-mp4

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Can Biosimilars Help Reduce America’s Medical Debt? June 23, 2022
Phase 3 Data on Samsung Bioepis’ Eculizumab Biosimilar Confirms Equivalence to Soliris June 13, 2022
Cedars-Sinai Health System Leverages Oncology Biosimilar Savings Through Its EHR June 10, 2022
Federal Trade Commission to Investigate PBM Practices June 8, 2022
Samsung Bioepis and Biogen Announce Launch of First Ranibizumab Biosimilar in US June 2, 2022
Partners Amneal and Kashiv Score Approval From FDA for Their Pegfilgrastim Biosimilar May 31, 2022
What Does Success Look Like in the Biosimilar Arena? May 27, 2022
More Confirmation that Payers Will Cover Beyond the Skinny Label May 16, 2022
Competition Squeezes Coherus’ Pegfilgrastim Revenues: Big Expectations for its On-Body Injector May 11, 2022
Will a Pharmacy Benefit Design Someday Include a Biosimilar Tier? Not Likely, and Here’s Why May 3, 2022

Recent Comments

	Drew on FDA’s Gottlieb Announces Impor…
	Phase 3 Data on Sams… on Amgen Settles With Alexion on…
	Samsung Bioepis and… on Ophthalmology Biosimilars May…
	Partners Amneal and… on Competition Squeezes Coherus’…
	More Confirmation th… on Denosumab Biosimilar Competito…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

The Evolution of the Biosimilars Market
Biosimilar Approval Status
The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
Ustekinumab Biosimilars Update
Can Biosimilars Help Reduce America’s Medical Debt?
Who Are the Key Aflibercept Biosimilar Players to Watch?
Don’t Expect All-Out Biosimilar Competition for Herceptin—Just Yet
Ogivri
The Interesting Scenario for a Tysabri® Biosimilar for Multiple Sclerosis
Phase 3 Data on Samsung Bioepis’ Eculizumab Biosimilar Confirms Equivalence to Soliris

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2022 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.